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Abstract
Background: In this study, we assess how effective pandemic and trivalent 2009-2010 seasonal vaccines were in preventing
influenza-like illness (ILI) during the 2009 A(H1N1) pandemic in France. We also compare vaccine effectiveness against ILI
versus laboratory-confirmed pandemic A(H1N1) influenza, and assess the possible bias caused by using non-specific
endpoints and observational data.
Methodology and Principal Findings: We estimated vaccine effectiveness by using the following formula: VE = (PPV-PCV)/
(PPV(1-PCV)) 6 100%, where PPV is the proportion vaccinated in the population and PCV the proportion of vaccinated
influenza cases. People were considered vaccinated three weeks after receiving a dose of vaccine. ILI and pandemic A(H1N1)
laboratory-confirmed cases were obtained from two surveillance networks of general practitioners. During the epidemic,
99.7% of influenza isolates were pandemic A(H1N1). Pandemic and seasonal vaccine uptakes in the population were
obtained from the National Health Insurance database and by telephonic surveys, respectively. Effectiveness estimates were
adjusted by age and week. The presence of residual biases was explored by calculating vaccine effectiveness after the
influenza period. The effectiveness of pandemic vaccines in preventing ILI was 52% (95% confidence interval: 30–69) during
the pandemic and 33% (4–55) after. It was 86% (56–98) against confirmed influenza. The effectiveness of seasonal vaccines
against ILI was 61% (56–66) during the pandemic and 19% (210–41) after. It was 60% (41–74) against confirmed influenza.
Conclusions: The effectiveness of pandemic vaccines in preventing confirmed pandemic A(H1N1) influenza on the field was
high, consistently with published findings. It was significantly lower against ILI. This is unsurprising since not all ILI cases are
caused by influenza. Trivalent 2009-2010 seasonal vaccines had a statistically significant effectiveness in preventing ILI and
confirmed pandemic influenza, but were not better in preventing confirmed pandemic influenza than in preventing ILI. This
lack of difference might be indicative of selection bias.
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Estimating the field effectiveness of influenza vaccines (VE)
poses specific challenges for the 2009 A(H1N1) pandemic. In
particular, both pandemic and seasonal vaccination campaigns
took place during the epidemic and, as a consequence, vaccine
coverage changed through time, both in influenza cases and in the
population as a whole.
In France, pandemic vaccination conformed to a priority list
established by public health authorities based on exposure and/or
transmission probability, or on risk of complication subsequent to
influenza [1]. The priority allocation of pandemic vaccines is
shown in Figure 1, along with the evolution of vaccine coverage
over time, by broad age categories. Medical and paramedical staffs
working in hospitals were first called, on October 20
th (week 43).
Individuals working with ambulatory patients presenting with
influenza or working with patients at high risk of complication for
influenza were called on November 2
nd (week 45). Risk factors of
complication, stated in a High Committee of Public Health advice,
on September 7
th 2009, were: pregnancy (in particular from the
second trimester), obesity, and chronic conditions such as bronco-
pulmonary diseases, heart diseases, diabetes and immunosuppres-
sion [2]. On November 12
th (week 46) all other health care
professional were called (880,000), as well as all persons in contact
with infants younger than six month-old (1,200,000), child-
minders working with children under three year-old (500,000),
and every person between six months and 64 years of age with a
risk factor (2,815,000). Pregnant women from their second
trimester and 6- to 23 month-old children without risk factor
were called on November 20
th (week 47). High school pupils were
called on November 25
th (week 48). People over 65 year-old with a
risk factor (3,200,000) and children older than 23 month-old
(7,700,000) and were called in week 49. Finally, adults over 18
year-old without a risk factor were called in week 53 (39,000,000).
In the end, 63,295,000 persons had been called to vaccination
centers to receive a pandemic influenza vaccine: all the French
population, except infants younger than 6 month-old.
Seasonal vaccines were available to everyone at high risk of
seasonal influenza related complications, from September 21
st
(week 39/2009). For both vaccines, most vaccinations were
completed by the end of January 2010.
In France, influenza-like illness (ILI) incidence has been
monitored since 1984 by the Sentinelles network, a surveillance
system based on sentinel general practitioners (GPs) [3]. ILI
incidence crossed the epidemic threshold in week 37/2009, while
detection of 2009 pandemic A(H1N1) viruses remained sporadic
until week 42 (see Figure 2). ILI incidence peaked in week 49 and
fell below the epidemic threshold in week 53. During the epidemic,
the pandemic strain was dominant (99.7%) among influenza virus
isolates [4]. In the first weeks of the pandemic, the sharpest
increase in ILI incidence was observed in children under five year-
old. After five weeks, 5 to 14 year-old children became the most
affected group. The biggest difference between age-specific
incidence rates was observed at the peak of the epidemic. It can
be seen in Figure 2 that adults over 65 year-old were almost
unaffected by the pandemic wave in France.
The purpose of this study was to assess how effective the
pandemic and 2009-2010 trivalent seasonal vaccines were in
preventing ILI on the field during the 2009-2010 season, using
surveillance data. To evaluate how using ILI instead of a more
specific influenza endpoint biased VE estimates, we conducted a
validation study on a sample of laboratory-confirmed A(H1N1)
influenza. We also assessed the existence of selection biases by
estimating VE outside the influenza-circulating period.
Methods
The Orenstein’s screening method was used to calculate vaccine
effectiveness with the following formula:
VE~
PPV{PCV
PPV 1{PCV ðÞ
|100%,
wherePCV is the proportion of vaccinated among influenza cases and
PPV is the proportion of vaccinated among the population [5,6]. PPV
was obtained from administrative sources. Two influenza datasets
were used: one of clinically defined ILI cases, and one of laboratory-
confirmed pandemic A(H1N1) influenza cases.
One injection was considered sufficient to confer a vaccinated
status [7,8]. Because influenza vaccines were not given to children
under six month-old, they were excluded from the study.
Individuals with missing age or vaccination status were also
excluded.
Study period
For ILI data, an epidemic and a post-epidemic study period
were defined for each vaccine. The epidemic study period began
three weeks after the start of the vaccination campaign: in week
42/2009 (October 12
th) for seasonal vaccines and in week 46/
2009 (November 9
th) for pandemic vaccines, and lasted until week
52/2009, end of the epidemic. The post-epidemic study period
started in week 05/2010 (February 1
st) and lasted until week 34/
2010 (August 29
th). Weeks 53/2009 to 04/2010 constituted a
‘‘washout period’’ since residual circulation of influenza viruses
was observed even though the epidemic itself was over. Study
periods are shown in Figure 1 and 2.
For laboratory-confirmed data, a single study period, spanning
weeks 46/2009 to 04/2010, was defined.
Case recruitment
ILI cases were reported by Sentinelles GPs in France excluding
overseas territories but including Corsica, as part of a surveillance
routine using the following definition: ‘‘sudden onset of fever
.39uC( .102uF) with respiratory signs and myalgia’’ [3].
Laboratory-confirmed influenza cases in France excluding
Corsica and overseas territories were reported by physicians from
the Regional Groups of Influenza Observation (GROG) as part of a
surveillance routine. GROG is a network of private-practice GP
and pediatricians dedicated to the virological surveillance of
influenza [9]. Corsican laboratory-confirmed influenza cases were
reported by Sentinelles GPs [10]. Nasopharyngeal swabs were
collected through a randomized selection routine. Doctors
included the first patient of each week, of any age (Sentinelles
protocol) or of a personally assigned age group among 0–4, 5–14,
15–64, and $65 year-old (GROG protocol). Only patients
presenting between 0 and 7 days after symptom onset were
swabbed.
GROG doctors swabbed patients presenting with acute respira-
tory infection, defined as: sudden onset of a respiratory sign
(cough, rhinitis, coryza,…) and a systemic sign evoking an
infection (fever, asthenia, headache, myalgia, faintness). Corsican
Sentinelles GPs swabbed patients presenting with ILI according to
the Sentinelles definition. Swabs were analyzed in 11 laboratories,
depending on the region of swabbing (two national reference
centers and nine laboratories), by real-time polymerase chain
reaction and/or culture.
For both ILI and laboratory-confirmed influenza cases, the
following information was included: date of consultation, age,
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a logical indicating whether the time from vaccination to
consultation was #3o r.3 weeks. The viral strain was known
for laboratory-confirmed influenza cases.
Population data
The pandemic vaccine coverage in the population was calculated
from the National Health Insurance database (Caisse Nationale
d’Assurance Maladie). The provided database contained weekly
Figure 1. Weekly coverage of pandemic and seasonal vaccines in the population throughout the study period. Red curves: vaccine
coverage in the 6 month- to 4 year-old age group; Blue: in the 5 to 14 year-old age group; Green: in the 15 to 64 year-old age group; Violet: in the
$65 year-old age group. Pandemic vaccination targeted different at-risk groups, which were called in turn, according to a calendar established by
French public health authorities. The principal steps of this calendar are outlined below the figure. Grey hatched area: epidemic study period for the
effectiveness of pandemic vaccines (weeks 46/2009 to 52/2009); Pink area: epidemic study period for seasonal vaccines (weeks 42/2009 to 52/2009);
Blue area: post-epidemic study period for pandemic and seasonal vaccines (weeks 05/2010 to 34/2010).
doi:10.1371/journal.pone.0019621.g001
Vaccine Effectiveness on 2009 A(H1N1) Flu
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19621counts of all persons vaccinated in France (excluding overseas
territories and includingCorsica) with a pandemic vaccine,from the
start of the vaccination campaign to week 18 of 2010. Detailed
coverage was provided for nine age groups: 6 month- to 4 year-old,
5–14, 15–24, 25–34, 35–49, 50–64, 65–69, 70–74, and $75 year-
old. Counts from weeks 19 to 34 of 2010 were assumed to be equal
tothoseduringweek18, sincethedatashowthatveryfewpandemic
vaccinations were completed after winter.
Pandemic vaccine coverage at week w, for age group g,
PV pjw,g

, was calculated as:
PV pjw,g

~
vp,g,w
popg

;
with vp,g,w the number of people in age group g vaccinated with the
pandemic vaccine before or during week w, and popg the
population size of age group g in 2009 in France (with Corsica,
without overseas territories).
This vaccine coverage was monotonically increasing since
1) once vaccinated, people remained as such throughout the
season and 2) the database contained all people vaccinated with a
pandemic vaccine, so that no random fluctuation was present.
For seasonal vaccines, a similar database was not maintained by
the National Health Insurance. Instead, vaccine coverage in the
population was estimated each month from September 2009 to
April 2010 by the Health Surveillance Institute (Institut de Veille
Sanitaire, InVS) using computer-assisted telephone surveys. Each
month a random sample from the French population (excluding
overseas territories and including Corsica) were interviewed during
an, on average, 11 day window. During the first stage of each
survey, the sampling frame was the telephone numbers list,
stratified by region and town size. At the second stage, the
sampling frame was household residents, stratified by age (,5
years, $5 years). Each month around 800 questionnaires were
filled in. Details of the sample design are provided elsewhere [11].
Pandemic vaccination status was also asked from November 2009,
enabling identification of the proportion of people vaccinated with
both vaccines, PV p\Vsjw,g

.
For the purpose of calculating the weekly seasonal vaccine
coverage, we began by attributing the interview data to the weeks
that accounted for most days of the interview windows. In other
words, using the interview data, we first estimated the proportion
of people vaccinated with seasonal vaccines, PV sjw,g ðÞ , and co-
vaccinated with pandemic and seasonal vaccines, PV p\Vsjw,g

,
for weeks 38, 42, 47 and 50 of 2009, and 2, 7, 11 and15 of 2010.
We then fitted logistic functions to these data points to obtain
smoothed, monotonically increasing weekly predictions of vaccine
coverage for all weeks in the study period: ~ P PV sjw,g ðÞ and
~ P PV p\Vsjw,g

. To account for the end of the vaccination
Figure 2. Weekly ILI incidence rates during the 2009–2010 pandemic in France (including Corsica, excluding overseas territories).
Black curve: national ILI incidence rate and 95% confidence interval. Red curve: national ILI incidence rate in the 0 to 4 year-old age group; Blue: in the
5 to 14 year-old age group; Green: in the 15 to 64 year-old age group; Violet: in the $65 year-old age group.
doi:10.1371/journal.pone.0019621.g002
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vaccinations, were constrained to remain stable respectively from
week 5 and week 11 of 2010.
Finally, the weekly coverage of seasonal vaccines in people that
did not get the pandemic vaccine, PV sjw,g,  V Vp

, was calculated
as:
PV sjw,g,  V Vp

~
P(Vs\  V Vpjw,g)
P   V Vpjw,g
 ~
~ P P(Vsjw,g){~ P P(Vp\Vsjw,g)
1{PV pjw,g

Estimation of field vaccine effectiveness
We used Farrington’s implementation of the screening method
to estimate VE adjusted on age and time [12]. In brief, VE was
estimated with a logistic regression model allowing a different
offset in each age6time strata. Age was divided into nine strata (6
month- to 4 year-old, 5–14, 15–24, 25–34, 35–49, 50–64, 65–69,
70–74 and $75 year-old), and time was divided into one week
strata.
A consensus view is that a period of at least 14 days is needed to
achieve a protective concentration of antibody after influenza
vaccination, but this timeline may vary [13]. Herein, for pandemic
and seasonal influenza vaccines, individuals were considered
vaccinated three weeks after receiving a dose of vaccine, and
unvaccinated if they had received no vaccine or if the vaccine had
been given in the last three weeks.
In practice, for the calculation of VE in a week t, we compared
the proportion of population vaccinated for more than three weeks
at week t to the proportion of influenza cases vaccinated for more
than three weeks that were seen by sentinel GPs in week t. Figure 1
shows the proportion of vaccinated in the population (plain lines),
and the proportion of population that has been vaccinated for
more than three weeks (dashed lines).
Since delay from injection was missing for some influenza cases,
we ran two analyses. In the first one we assumed that these cases
had received influenza vaccination in the three weeks preceding
the consultation, and included them as unvaccinated. In the
second analysis, we assumed that they had been vaccinated for
more than three weeks and we included them as vaccinated. We
explored in a third analysis what vaccine effectiveness was when
vaccination was considered completed immediately after the
injection of one vaccine dose. Because the question related to
the interval between consultation and vaccination was dichoto-
mized at three weeks, we could no further explore the protection
timeline.
As trivalent 2009–2010 seasonal vaccines were expected to be
less specific of 2009 A(H1N1) than pandemic vaccines, effective-
ness of the seasonal vaccines was calculated only using those
individuals that did not receive pandemic vaccination. As a
sensitivity analysis, a second analysis included those cases.
Assessment of bias
The use of ILI, a non-specific influenza outcome, as a primary
endpoint for estimating the effectiveness of influenza vaccines can
bias VE estimates downward. Indeed, if only 50% of ILI cases are
caused by influenza, a hundred percent effective influenza vaccine
will have at most 50% effectiveness in preventing ILI: as the
specificity of the outcome decreases, so do VE estimates [14–16].
To assess this first source of bias, we compared VE estimates
obtained using the ILI case sample provided by Sentinelles GPs to
VE estimates obtained using the confirmed pandemic A(H1N1)
influenza cases provided by GROG and some Sentinelles GPs.
A second source of bias was identified in that we used
observational data of patients consulting a GP for an influenza
episode, and compared their vaccine coverage to the one in the
general population. Patients consulting a GP for an influenza
episode might not be comparable to the rest of the population. In
particular, if people vaccinated with influenza vaccine consulted
differently than the rest of the population for an influenza episode,
because of comorbidities or because of a different propensity to
seek care for example, this could be a confusion factor when
estimating VE. As suggested by several authors, such a selection
bias should affect VE estimated on GP data during the influenza-
circulation period as well as VE estimated outside this period [17–
22]. This is particularly interesting when using ILI, as influenza
vaccine effectiveness in preventing ILI should be null outside the
influenza-circulation period, if no bias was present. We therefore
calculated VE against ILI after the influenza epidemic period, as
an indication of selection bias in our data. As no vaccine was given
before the epidemic start, pre-epidemic VE could not be assessed.
We did not calculate VE against laboratory-confirmed A(H1N1)
influenza outside the influenza-circulating period.
Results
ILI cases
Pandemic vaccines. During the study period, Sentinelles GPs
reported 7586 ILI cases above 6 month-old, with information on
age and pandemic vaccine status, which were included in the
pandemic vaccines analysis. Among them, 172 (2%) were
vaccinated. Detailed numbers by study period and age group
are presented in Table 1.
Pandemic influenza vaccination had been done in the three
weeks preceding the consultation for 108 vaccinated cases (63%),
more than three weeks before consultation for 56 cases (33%), or
at an unknown date for 8 of them. During the pandemic period,
67% (29/43) of the 6 month- to 4 year-old ILI cases were
vaccinated in the three weeks preceding the consultation, versus
77% (34/44) of the 5 to14 year-old and 86% (42/49) of the 15 to
64 year-old (Fisher’s test p=0.12). None of the two vaccinated ILI
cases $65 year-old reported by Sentinelles GPs during the
pandemic had been vaccinated for more than three weeks.
Six month to four year-old children mostly received the non-
adjuvanted PanenzaH vaccine (21/48 i.e. 44%); four of them (8%)
received the adjuvanted PandemrixH vaccine; trademark was
unknown for the remaining 23 ones. On the contrary, 5 to 14
year-old children mostly received the PandemrixH vaccine (22/53
i.e. 42%); nine of them (17%) received the non-adjuvanted
PanenzaH vaccine; trademark was unknown for the remaining 22
ones. Most cases aged15 year-old and over received the
PandemrixH vaccine (43/71 i.e. 61%); four had the PanenzaH,
four the Q-Pan H1N1H and one the FocetriaH vaccine; trademark
was unknown for 19. Most cases received one dose of vaccine
(154/172 i.e. 90%). Eight cases received two doses of vaccines:
three children below 15 year-old and five 35 to 64 year-old adults.
Seasonal vaccines. For the purpose of estimating the
effectiveness of seasonal influenza vaccines, 9564 cases were
eligible. Among them, 540 (6%) were vaccinated. Detailed
numbers by study period and age group are presented in
Table 2. Vaccination had been done in the three weeks
preceding the consultation for 115 cases (21%), more than three
weeks before consultation for 401 cases (74%), or at an unknown
date for 24 of them. Sixty-one of them (11%) were also vaccinated
with the pandemic vaccine, while 465 (86%) were not, the
remaining 14 patients having not answered the pandemic
vaccination question.
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Pandemic vaccines. Together, the GROG and Sentinelles
samples provided 838 laboratory-confirmed pandemic A(H1N1)
influenza cases $6 month-old that were described for pandemic
vaccination and age, and were included in the analysis of
pandemic vaccines. We did not include in the analysis those
influenza isolates that were not typed (18), were of not-subtyped
type A (26), or were of subtype A(H3N2) (one). No B strain was
present in the sample.
Twenty-five of the included A(H1N1) cases were vaccinated
(3%). Detailed numbers by age group are presented in Table 3. It
is noteworthy that none of the five confirmed A(H1N1) cases aged
$65 year-old that were included in the study had received a
pandemic vaccine.
Six month- to four year-old children mostly received the non-
adjuvanted PanenzaH vaccine (12/13 i.e. 92%); only one of them
received the adjuvanted PandemrixH vaccine. Four of the nine
vaccinated children between five and fourteen year-old were given
the PanenzaH vaccine (44%); three receive the PandemrixH
vaccine (33%); two received a pandemic vaccine of unknown
brand. Among the three vaccinated cases above 15 years, two
received the PandemrixH and one the PanenzaH vaccine.
Vaccination had been done in the three weeks preceding the
consultation for 20 of the 25 vaccinated cases (80%), before that delay
for two cases (8%), or at an unknown date for three of them (12%).
Eighty-five percent (11/13) of the 6 month- to 4 year-old laboratory-
confirmed cases were vaccinated in the three weeks preceding the
consultation, versus 89% (8/9) of the 5 to14 year-old and 33% (1/3)
of the 15 to 64 year-old (Fisher’s test p=0.16). Twenty-three cases
(92%) had received one dose of vaccine, the other two cases did not
precise this information. None has received two injections.
Seasonal vaccines. The laboratory-confirmed case sample
contained 856 pandemic A(H1N1) cases that were described for
age and seasonal vaccine status and could be included in the study.
Fifty-one of them (6%) were vaccinated. Detailed numbers by age
group are presented in Table 4.
Table 1. Pandemic vaccine uptake among ILI cases included in the pandemic vaccine effectiveness analysis.
Epidemic study period Post-epidemic study period
Vaccinated for Vaccinated for
Age
group
Total
described
Total
vaccinated .3 weeks Unknown #3 weeks
Total
described
Total
vaccinated .3 weeks Unknown #3 weeks
6 m–4 y 875 43 13 1 29 51 5 4 1 0
5–14 2740 44 6 4 34 89 9 7 0 2
15–24 1250 13 1 2 10 55 2 2 0 0
25–34 763 7 1 0 6 80 3 3 0 0
35–49 937 19 2 0 17 135 11 11 0 0
50–64 378 8 1 0 7 68 6 5 0 1
65–69 46 0 0 0 0 11 0 0 0 0
70–74 28 2 0 0 2 10 0 0 0 0
$75 55 0 0 0 0 15 0 0 0 0
Total 7072 136 24 7 105 514 36 32 1 3
doi:10.1371/journal.pone.0019621.t001
Table 2. Seasonal vaccine uptake among ILI cases included in the seasonal vaccine effectiveness analysis.
Epidemic study period Post-epidemic study period
Vaccinated for Vaccinated for
Age
group
Total
described
Total
vaccinated .3 weeks Unknown #3 weeks
Total
described
Total
vaccinated .3 weeks Unknown #3 weeks
6 m–4 y 1123 18 12 1 5 54 3 3 0 0
5–14 3447 73 43 2 28 100 4 4 0 0
15–24 1571 48 38 2 8 59 3 3 0 0
25–34 1020 34 21 4 9 83 6 5 0 1
35–49 1205 95 69 6 20 145 24 20 1 3
50–64 486 95 72 4 19 76 21 20 0 1
65–69 57 23 18 1 4 11 3 2 1 0
70–74 36 23 14 1 8 11 8 8 0 0
$75 65 48 40 0 8 15 11 9 1 1
Total 9010 457 327 21 109 554 83 74 3 6
doi:10.1371/journal.pone.0019621.t002
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consultation for 10 of the vaccinated cases (20%), more than three
weeks before consultation for 29 cases (57%), or at an unknown
date for 12 of them (24%). All confirmed pandemic A(H1N1) cases
$65 year-old included in the study had received the seasonal
vaccine. Five (10%) of the cases vaccinated with a seasonal vaccine
had also received a pandemic vaccine, while 43 (84%) had not.
Field vaccine effectiveness
As exposed in the method section, three analyses were carried
out. 1) In the first one (primary one), vaccination is considered
completed three weeks after injection and all influenza cases with
missing injection date are treated as unvaccinated. 2) As a first
sensitivity analysis, influenza cases with missing vaccination date
are treated as vaccinated. 3) Vaccination is considered completed
immediately after the injection of one vaccine dose.
Since, during the pandemic, most reported influenza cases were
vaccinated in the three weeks that preceded the consultation,
considering missing injection date as belonging to the last three
weeks, as was done in the first analysis, might be the more realistic
option. The first analysis is thus considered the primary one, and
its main results are reported hereafter. Detailed results of the three
analyses are provided in Table 5 and Table 6.
Effectiveness of pandemic vaccines. When vaccination
was considered completed three weeks after the injection of one
vaccine dose, the effectiveness of pandemic vaccine in preventing
ILI was 52% (95% confidence interval 30–69) in the epidemic
period, and 33% (4–55) in the post-epidemic period. When
vaccination was considered completed immediately after injection,
pandemic vaccine effectiveness in preventing ILI was 54% (45–61)
in the epidemic period and 24% (27–47) in the post-epidemic
period.
When vaccination was considered completed three weeks after
injection, pandemic vaccine effectiveness in preventing laboratory-
confirmed pandemic A(H1N1) influenza was 86% (56–98). When
vaccination was considered completed immediately after injection,
pandemic vaccine effectiveness in preventing laboratory-con-
firmed pandemic A(H1N1) influenza was 49% (25–67).
The effectiveness of pandemic vaccines in preventing ILI and
confirmed pandemic A(H1N1) influenza in different age groups is
presented in Table 5. As no confirmed case above 65 year-old was
vaccinated, the age-specific effectiveness of pandemic vaccine in
this age group is not presented.
Effectiveness of seasonal vaccines. In the primary analysis
of the field effectiveness of trivalent 2009–2010 seasonal vaccine,
shown below, we excluded those individuals that received
Table 3. Pandemic vaccine uptake among laboratory-confirmed cases included in the pandemic vaccine effectiveness analysis.
Vaccinated for
Age group Total described Total vaccinated .3 weeks Unknown #3 weeks
6 m–4 y 209 13 0 2 11
5–14 339 9 1 0 8
15–24 93 1 1 0 0
25–34 78 0 0 0 0
35–49 85 0 0 0 0
50–64 29 2 0 1 1
65–69 2 0 0 0 0
70–74 0 0 0 0 0
$75 3 0 0 0 0
Total 838 25 2 3 20
doi:10.1371/journal.pone.0019621.t003
Table 4. Seasonal vaccine uptake among laboratory-confirmed cases included in the seasonal vaccine effectiveness analysis.
Vaccinated for
Age group Total described Total vaccinated .3 weeks Unknown #3 weeks
6 m–4 y 213 5 2 0 3
5–14 342 17 11 2 4
15–24 98 4 3 0 1
25–34 82 3 0 2 1
35–49 86 7 4 3 0
50–64 30 10 5 4 1
65–69 2 2 1 1 0
70–74 0 0 0 0 0
$75 3 3 3 0 0
Total 856 51 29 12 10
doi:10.1371/journal.pone.0019621.t004
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Age group FVE (%) 95% CI
ILI, epidemic period
Vaccinated for #3 weeks or at an unknown date are considered unvaccinated 6m – 4y 1 2 ( 247–53)
5–14 53 (1–82)
15–64 77 (51–92)
$65 100 –
All ages 52 (30–69)
Vaccinated for #3 weeks are considered unvaccinated. Vaccinated at an unknown date are
considered vaccinated.
6 m–4 y 5 (257–47)
5–14 18 (247–60)
15–64 68 (38–86)
$65 100 –
All ages 38 (13–58)
All vaccinees are considered vaccinated, regardless of the injection date 6 m–4 y 53 (36–66)
5–14 59 (46–70)
15–64 49 (33–62)
$65 30 (2124–88)
All ages 54 (45–61)
ILI, post-epidemic period
Vaccinated for #3 weeks or at an unknown date are considered unvaccinated 6 m–4 y 65 (14–90)
5–14 28 (245–70)
15–64 11 (238–47)
$65 100 –
All ages 33 (4–55)
Vaccinated for #3 weeks are considered unvaccinated. Vaccinated at an unknown date are
considered vaccinated.
6m – 4y 5 6 ( 22–85)
5–14 28 (245–70)
15–64 11 (238–47)
$65 100 –
All ages 31 (1–53)
All vaccinees are considered vaccinated, regardless of the injection date 6m – 4y 5 6 ( 22–85)
5–14 5 (278–56)
15–64 6 (244–43)
$65 100 –
All ages 24 (27–47)
Laboratory-confirmed influenza
Vaccinated for #3 weeks or at an unknown date are considered unvaccinated 6 m–4 y 100 –
5–14 72 (228–98)
15–64 74 (215–99)
All ages 86 (56–98)
Vaccinated for #3 weeks are considered unvaccinated. Vaccinated at an unknown date are
considered vaccinated.
6 m–4 y 69 (1–95)
5–14 72 (228–98)
15–64 48 (264–91)
All ages 64 (21–87)
All vaccinees are considered vaccinated, regardless of the injection date 6 m–4 y 44 (4–70)
5–14 44 (24–73)
15–64 69 (19–92)
All ages 49 (25–67)
doi:10.1371/journal.pone.0019621.t005
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Excluding pandemic
vaccine recipients
Including pandemic
vaccine recipients
Age group FVE (%) 95% CI FVE (%) 95% CI
ILI, epidemic period
Vaccinated for #3 weeks or at an unknown date are considered unvaccinated 6 m–4 y 77 (59–89) 72 (54–85)
5–14 84 (78–89) 87 (83–91)
15–64 52 (44–59) 47 (38–54)
$65 19 (214–42) 21 (210–44)
All ages 61 (56–66) 63 (58–67)
Vaccinated for #3 weeks are considered unvaccinated. Vaccinated at an
unknown date are considered vaccinated.
6 m–4 y 75 (56–87) 70 (51–84)
5–14 83 (77–88) 87 (82–90)
15–64 47 (39–55) 42 (33–50)
$65 14 (220–38) 17 (216–40)
All ages 58 (53–63) 60 (55–64)
All vaccinees are considered vaccinated, regardless of the injection date 6 m–4 y 67 (44–82) 62 (42–77)
5–14 69 (60–76) 79 (73–83)
15–64 41 (33–49) 41 (33–48)
$65 27( 250–23) 22( 243–27)
All ages 47 (42–53) 54 (49–58)
ILI, post-epidemic period
Vaccinated for #3 weeks or at an unknown date are considered unvaccinated 6m – 4y 5 4 ( 2112–97) 218 (2220–71)
5–14 61 (222–94) 61 (7–88)
15–64 7 (232–37) 7 (227–33)
$65 25 (252–62) 39 (223–70)
All ages 19 (210–41) 19 (25–39)
Vaccinated for #3 weeks are considered unvaccinated. Vaccinated at an
unknown date are considered vaccinated.
6m – 4y 5 4 ( 2112–97) 218 (2220–71)
5–14 61 (222–94) 61 (7–88)
15–64 7 (232–37) 4 (230–31)
$65 3 (299–52) 22 (262–61)
All ages 14 (216–38) 15 (211–35)
All vaccinees are considered vaccinated, regardless of the injection date 6m – 4y 5 4 ( 2108–97) 216 (2216–72)
5–14 61 (223–94) 62 (8–88)
15–64 24( 247–28) 27( 244–22)
$65 26( 2119–47) 17 (272–59)
All ages 5 (227–31) 7 (221–29)
Laboratory-confirmed influenza
Vaccinated for #3 weeks or at an unknown date are considered unvaccinated 6 m–4 y 74 (18–96) 77 (29–96)
5–14 60 (25–82) 65 (40–82)
15–64 64 (36–82) 59 (29–78)
All ages 60 (41–74) 61 (44–74)
Vaccinated for #3 weeks are considered unvaccinated. Vaccinated at an
unknown date are considered vaccinated.
6 m–4 y 74 (18–96) 77 (29–96)
5–14 50 (11–75) 59 (31–78)
15–64 29 (211–57) 24 (216–53)
All ages 38 (14–57) 43 (23–60)
All vaccinees are considered vaccinated, regardless of the injection date 6m – 4y 3 1 ( 251–75) 46 (218–81)
5–14 26 (222–59) 48 (18–69)
15–64 22 (218–51) 25 (212–52)
All ages 20 (27–42) 35 (14–52)
doi:10.1371/journal.pone.0019621.t006
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them are shown in the last column of Table 6.
When vaccination was considered completed three weeks after
the injection of one vaccine dose, the effectiveness of seasonal
vaccine in preventing ILI was 61% (56–66) in the epidemic period,
and 19% (210–41) in the post-epidemic period. When vaccination
was considered completed immediately after injection, seasonal
vaccine effectiveness in preventing ILI was 47% (42–53) in the
epidemic period and 5% (227–31) in the post-epidemic period.
When vaccination was considered completed three weeks after
the injection of one vaccine dose, the effectiveness of seasonal
vaccine in preventing laboratory-confirmed pandemic A(H1N1)
influenza was 60% (41–74). When vaccination was considered
completed immediately after injection, seasonal vaccine effective-
ness in preventing laboratory-confirmed pandemic A(H1N1)
influenza was 20% (27–42).
The effectiveness of seasonal vaccines in preventing ILI and
confirmed pandemic A(H1N1) influenza by age groups is
presented in Table 6. Since only five laboratory-confirmed
pandemic A(H1N1) cases older than 65 year-old were included
in the analysis, we do not present age-specific VE for this age
group.
Discussion
We obtained estimates of vaccine effectiveness by comparing
vaccine coverage of influenza cases (clinically defined or
biologically confirmed) to vaccine coverage of population samples,
using Orenstein’s screening method [5,12]. To allow for a delay
between the injection of a vaccine dose and immunization,
vaccination was considered completed only three weeks after
injection. In other words, in our primary analysis, individuals
vaccinated for less than three weeks were considered unvaccinat-
ed. As a consequence of the late vaccination campaigns, the
number of vaccinations we could consider completed during the
pandemic was low.
Pandemic vaccine effectiveness
We found that pandemic vaccines had a field effectiveness of
86% (56–98) in preventing laboratory-confirmed pandemic
A(H1N1) influenza, which is in the range of previously reported
values [7,8,23-26]. More specifically, our estimates are slightly
above the results of a multicenter case-control study conducted in
seven European countries and are above the results of a case-
control study conducted in the United Kingdom, which both
found VE=72% [8,23]. They are also above the VE found by a
Korean study, namely 73% [24]. However, they are below the
estimates from a Scottish cohort study (95%) [25], a German study
based on the screening method (83–97%) [26] and a Canadian
test-negative incident case-control study (.90%) [7].
We found that pandemic vaccines had a significantly lower
effectiveness in preventing ILI than in preventing confirmed
A(H1N1) influenza: 52% (30–69) versus 86% (56–98). This is
unsurprising as only a part of the 2009–2010 ILI cases were due to
pandemic A(H1N1) influenza and therefore could be prevented by
the pandemic vaccine. This part was estimated between 30% and
55%, depending on the country [27,28].
The effectiveness of pandemic vaccines in preventing ILI and
confirmed influenza seemed to vary with age, yet not significantly
and in no reproducible order through our different analysis. Since
few reported influenza cases were vaccinated, large confidence
intervals surround our age-specific VE estimates. In particular, no
confirmed A(H1N1) case and only two ILI cases above 65 year-old
were vaccinated with the pandemic vaccine. Indeed, elderly
people were not a priority target group for pandemic vaccination
and were called late to vaccination centers (Figure 1). Estimations
of vaccine effectiveness in this subgroup are therefore highly
uncertain.
As others, we considered that one dose of pandemic vaccine was
sufficient to provide immunization for all age classes
[7,8,23,24,26]. However, it was shown that a single dose of
pandemic A(H1N1) vaccine was more immunogenic in children
older than three years than in younger children, and that a second
dose was needed to reach seroprotection and seroconversion rates
of 90–99% in both of these age groups [29].
Influenza vaccines are theoretically expected to be more
effective three weeks after their injection than immediately after.
We did observe a significantly higher effectiveness of pandemic
vaccines in preventing laboratory-confirmed pandemic A(H1N1)
influenza when only vaccinations dating back to more than three
weeks were considered completed than when treating all
vaccinations as completed: 86% (56–98) versus 49% (25–67).
Yet, we did not find a significant difference in that respect
regarding the effectiveness of pandemic vaccines against ILI: 52%
(30–69) versus 54% (45–61), which is a first indication of the
presence of biases in the estimation.
Seasonal vaccine effectiveness
We found that the 2009–2010 seasonal vaccines had a
significant effectiveness in preventing laboratory-confirmed influ-
enza: VE=60% (41–74). Unlike pandemic vaccines, seasonal
vaccines were not significantly better in preventing laboratory-
confirmed pandemic A(H1N1) influenza than in preventing ILI:
respectively VE=60% (41–74) versus VE=61% (56–66). This
result cannot be explained by ILI comprising an appreciable
number of seasonal influenza cases against which seasonal vaccine
could have proven effective: more than 99% of influenza isolates
during the 2009-2010 season were pandemic A(H1N1) [4]. This
result might, instead, indicate that our effectiveness estimates of
seasonal vaccines are driven by biases, in particular case selection
biases. Indeed, the population that yearly vaccinates against
seasonal influenza might be distinct from the rest of the
population, in particular in its propensity to consult. This could
induce a selection bias, since influenza cases are recruited through
GPs. Therefore, the absence of adjustments in our study, when
most studies adjusted by comorbidities and previous vaccination,
could be a reason for the high effectiveness we observed.
We identified a source of bias in our seasonal vaccine study in
that we used underestimated seasonal vaccine coverage for the 6
month- to 4 year-old population age group. Indeed, the vaccine
coverage data provided by the InVS study concerned the 0–4
year-old age group, even if 0 to 6 month-old children were not
concerned by seasonal influenza vaccination. Nevertheless, this
should result in under-estimating, not over-estimating, vaccine
effectiveness in this age group.
Our results come within a succession of contradictory evidences
regarding the effectiveness of seasonal vaccines against pandemic
2009 A(H1N1) influenza. In a literature review by Viboud et al,
four studies of the 2008–2009 seasonal vaccines found no
protection against 2009 pandemic A(H1N1) influenza; two other
found a significant protection; two other found that 2008–2009
seasonal vaccination increased the risk of contracting pandemic
2009 A(H1N1) influenza [30]. A subsequent paper evidenced a
moderate effectiveness of the 2008–2009 seasonal vaccines against
pandemic A(H1N1) mild outcomes (VE=42%, 29–53%) [31],
while another one put forward an increased risk (odds-ratio=2.45,
1.34–4.48) [32].
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most works found no protection against confirmed pandemic
A(H1N1) [8,23,33–36], while one found an effectiveness of 50%
(40–59) in preventing pandemic A(H1N1) related hospitalizations
[37].
Adjustments
We adjusted by age to take into account different vaccine
responses with age, and used weekly strata to account for the
evolution of vaccine coverage in the population throughout the
study period. As noted before, the lack of further adjustment could
result in biased VE estimates, both for ILI and confirmed
influenza. However, as our study was integrated in an ongoing
surveillance system based on GP voluntary reporting of ILI cases,
adjustment covariates were not collected in order to keep the
questionnaire as short as possible. As a compromise, only essential
covariates for VE calculation were asked to GPs: age, vaccine
status (pandemic and seasonal), delay since vaccination (dichoto-
mized at three weeks), and vaccine trademark (for pandemic
vaccine only). Considering the small number of reported
vaccinated influenza cases, pandemic VE was not calculated by
vaccine trademark.
We used a three weeks delay between vaccination and
consultation to differentiate vaccinated influenza cases fully
immunized from those that were still unprotected. This delay
might be too astringent: in most papers, a two week delay between
vaccination and symptom onset is used [7,23,24,26], as data on
seasonal influenza showed that protective antibodies were present
in over 90% of persons fourteen days after vaccination [13].
However, as the question used for ILI cases was ‘‘Is delay since
vaccination #3 weeks?’’, no data was available to make sensitivity
analysis.
Biases
Bias due to the use of a non-specific endpoint. ILI is a
non-specific proxy for influenza infection. Disposing of a
validation sample of laboratory-confirmed pandemic A(H1N1)
influenza cases allowed us to explore the bias in VE inherent to the
use of such a non-specific outcome. Regarding the effectiveness of
pandemic vaccines, the results are in accordance with the
theoretical principle which stipulates that, as the specificity of
the outcome decreases, so should the measured vaccine
effectiveness [14–16]. Effectiveness of seasonal vaccines,
however, did not show such a difference.
A few studies have used ILI as an endpoint for evaluating
influenza vaccine effectiveness on the field [38–41], although
laboratory-confirmed influenza is a more common endpoint. In
particular, a case-control study based on university students
reporting ILI episodes through a web interface evidenced a
significant reduction of ILI among vaccinated students during
seasonal influenza (adjusted odds ratio: 0.70, 95% confidence
interval 0.56–0.89) but not during non-influenza periods (adjusted
odds ratio: 0.98, 0.73–1.30) [42].
Herein, we do observe a lower effectiveness of pandemic
vaccines in preventing ILI after the epidemic period (VE=33%,
4–55); however, unlike in Nichol et al, the effectiveness remains
significantly above zero. As suggested by previous works, we can
attribute this overestimation to the presence of biases, such as
selection biases [17–22]. Stochastic variations due to our little
sample sizes are another possible explanation.
Sensitivity of the outcome ‘‘ILI consulting a GP’’ to track true
influenza is also an issue: asymptomatic cases, subclinical cases and
presentations different from the chosen ILI definition are missed.
Call et al reviewed the probabilities of presence of different
symptoms in influenza cases, i.e. the sensitivity of these symptoms
for detecting influenza: depending on the age group, they were
between 0.3 and 0.9, with lower sensitivities in the elderly [43].
Orenstein et al demonstrated in a simulation study that poorly
sensitive outcomes could lead to underestimation of field vaccine
effectiveness in three different observational designs [16]. Howev-
er, our analysis seems more subject to overestimation biases.
Bias due to incomparability of cases and population
sample. Another potential source of bias in our study is the
uncertain comparability of cases recruited by GPs with samples
drawn from the general population. To further assess the possible
lack of comparability between cases and population samples, an
alternative population sample taken directly among GPs usual
patients could be used for validation. To that effect, during 2010–
2011 influenza season, a cross-sectional survey at GPs offices will
be carried out to assess the vaccine coverage among Sentinelles GPs
patients.
Selection biases. As was visible in the results of seasonal
vaccine effectiveness, selection biases might be present in our study
design and bias result upwards. To try and further evidence these
selection biases, vaccine effectiveness against ILI was computed
after the influenza circulation period. Effectiveness of pandemic
vaccine during this period was significantly above zero (33%, 4–
57), although not significant in most age subgroups except in the
six to fourteen year-old group. Effectiveness of seasonal vaccines
was, as for it, not significant, whether overall (19%, 210–41) or in
each age subgroup. In conclusion, for both vaccine types, a
moderate vaccine effectiveness was found after the 2009 A(H1N1)
influenza virus stopped circulating at appreciable levels, which is
indicative of upward biases in our VE estimates, but this post-
pandemic effectiveness was mainly not statistically significant.
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